Caladrius Biosciences, Inc.
NASDAQ: CLBS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David Mazzo
- Employees
- 27
- Headquarters
- Basking Ridge, United States
- IPO year
- 1995
- Market cap
- $3.4M
- Website
- https://www.caladrius.com
Loading CLBS…
Loading profile data…Frequently asked questions about CLBS
What does Caladrius Biosciences, Inc. (CLBS) do?
Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical company primarily engaged in the development and commercialization of cellular therapies. These therapies aim to either reverse various diseases or stimulate the regeneration of compromised tissue. The company's pipeline includes several key investigational therapies: HON...
Where does CLBS trade?
Caladrius Biosciences, Inc. (CLBS) trades on the NASDAQ Capital Market.
What sector is CLBS in?
Caladrius Biosciences, Inc. (CLBS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Caladrius Biosciences, Inc.?
David Mazzo is the chief executive officer of Caladrius Biosciences, Inc. (CLBS).
Where is Caladrius Biosciences, Inc. headquartered?
Caladrius Biosciences, Inc. is headquartered in United States.
Does CLBS pay a dividend?
Yes — Caladrius Biosciences, Inc. (CLBS) paid a trailing twelve-month dividend of USD 0.56 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did CLBS go public?
Caladrius Biosciences, Inc. (CLBS) completed its initial public offering in 1995.